MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer treatment. It generates product candidates from proprietary platforms including DART and TRIDENT bispecific antibodies and antibody-drug conjugates (ADCs). Key pipeline assets include lorigerlimab, MGC026, and MGC028. The company also operates a commercial-scale cGMP antibody manufacturing facility and provides contract development and manufacturing services. Three partnered products—ZYNYZ, MARGENZA, and TZIELD—have received FDA approval.
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001125345-26-000017 | EDGAR | 72K words |
| 2025-03-20 | 2024-12-31 | 0001125345-25-000042 | EDGAR | 73K words |
| 2024-03-07 | 2023-12-31 | 0001125345-24-000060 | EDGAR | 76K words |
| 2023-03-15 | 2022-12-31 | 0001125345-23-000059 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001125345-22-000013 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001125345-21-000035 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001125345-20-000031 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001125345-19-000046 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001125345-18-000022 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0001125345-17-000041 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001125345-26-000056 | EDGAR | 22K words |
| 2025-11-12 | 2025-09-30 | 0001125345-25-000108 | EDGAR | 17K words |
| 2025-08-14 | 2025-06-30 | 0001125345-25-000101 | EDGAR | 15K words |
| 2025-05-13 | 2025-03-31 | 0001125345-25-000053 | EDGAR | 14K words |
| 2024-11-05 | 2024-09-30 | 0001125345-24-000160 | EDGAR | 16K words |
| 2024-08-06 | 2024-06-30 | 0001125345-24-000148 | EDGAR | 15K words |
| 2024-05-09 | 2024-03-31 | 0001125345-24-000088 | EDGAR | 13K words |
| 2023-11-06 | 2023-09-30 | 0001125345-23-000124 | EDGAR | 22K words |
| 2023-08-09 | 2023-06-30 | 0001125345-23-000108 | EDGAR | 22K words |
| 2023-05-09 | 2023-03-31 | 0001125345-23-000076 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001125345-22-000104 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001125345-22-000090 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001125345-26-000054 | EDGAR | 3K words |
| 2026-07-23 | 0001125345-26-000050 | EDGAR | 1K words |
| 2026-03-09 | 0001125345-26-000018 | EDGAR | 2K words |
| 2026-03-02 | 0001125345-26-000011 | EDGAR | 1K words |
| 2026-02-24 | 0001125345-26-000009 | EDGAR | 1K words |
| 2025-11-20 | 0001125345-25-000111 | EDGAR | 1K words |
| 2025-11-12 | 0001125345-25-000109 | EDGAR | 3K words |
| 2025-08-14 | 0001125345-25-000100 | EDGAR | 3K words |
| 2025-08-13 | 0001125345-25-000094 | EDGAR | 1K words |
| 2025-06-10 | 0001125345-25-000087 | EDGAR | 1K words |
227 total filings indexed. 195 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001125345 |
| Ticker | MGNX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.macrogenics.com |
| Listed | 2013-10-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MGNX (~200 tokens, structured JSON with cryptographic provenance)